Hydrogen gas inhalation ameliorates lung injury after hemorrhagic shock and resuscitation.
Duk Hwan Moon, Du-Young Kang, Seok Jin Haam, Tetsuya Yumoto, Kohei Tsukahara, Taihei Yamada, Atsunori Nakao, Sungsoo Lee · Journal of thoracic disease · 2019
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In rats, as shown in this study, a reduction of TNF-α and IL-1β by 2% hydrogen gas inhalation may ultimately reduce the incidence of lung injury from the onset of resuscitation. These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how inhaled hydrogen gas affected the outcomes measured in rats. as shown in this study, a reduction of TNF-α and IL-1β by 2% hydrogen gas inhalation may ultimately reduce the incidence of lung injury from the onset of resuscitation.
What the Researchers Studied
The researchers studied rats. The study used a preclinical animal experiment.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen concentration: 2% source-reported H₂ gas concentration; Source-reported hydrogen exposure: 2% source-reported H₂ gas concentration; 4 L/min H₂ flow (4000 mL/min H₂); via nasal cannula; reported treatment duration: 1 hour. as shown in this study, a reduction of TNF-α and IL-1β by 2% hydrogen gas inhalation may ultimately reduce the incidence of lung injury from the onset of resuscitation. In conclusion, inhalation of 2% hydrogen gas after HSR can minimize the extent of lung injury by inducing a decrease in the MPO activity—and consequently inhibiting the infiltration of neutrophils into the lungs—and by inducing a decrease in the infiltration of inflammatory cells into the lung tissues—and consequently suppressing the formation of proinflammatory mediators, such as IL-1β, TNF-α, iNOS, ICAM-1 and CCL2.
Why These Findings Matter
These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The research population or model was rats. The study used a preclinical animal experiment. The hydrogen delivery method was inhaled hydrogen gas. The source-reported hydrogen concentration was 2% source-reported H₂ gas concentration. The reported treatment duration was 1 hour.
Limitations and Safety
Reported limitations: This study has the following limitation to consider.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base. The original scholarly source is available at https://jtd.amegroups.org/article/view/27869/20895.